Mesoblast (ASX:MSB) completes $138 million private placement

02MarMarch 2, 2021

Mesoblast (ASX:MSB) completes $138 million private placement

Mesoblast (ASX:MSB) has entered into subscription agreements for a total of $138 million private placement, led by a strategic US investor group, SurgCenter Development.

The placement was conducted through the issue of 60 million shares at $2.30 a share, a 6.5 per cent discount to Mesoblast’s closing price on Thursday.

SurgCenter Development is one of the largest private operators of ambulatory surgical centres in the US specialising in spine, orthopaedic and total joint procedures.

The company has partnered in over 230 facilities, with a current portfolio of 80 operational facilities, located in over 20 states throughout the US.

Shares in Mesoblast (ASX:MSB) are trading 0.4 per cent higher at $2.47.

Source: Finance News Network

13MarMarch 13, 2023

Stocks of the Hour: Neuren Pharmaceuticals, Metro Mining, Meteoric Resources

13 Mar 2023 - A snapshot of the stocks on the move featuring Neuren Pharmaceuticals (ASX:NEU), Metro Mining (ASX:MMI) and Meteoric Resources (ASX:MEI).

03FebFebruary 3, 2020

Resolute (ASX:RSG) repays US$130 million bridge debt facility

03 Feb 2020 - Resolute Mining (ASX:RSG) has repaid its $130 million US dollar acquisition bridge facility.

22JunJune 22, 2020

Ramelius Resources (ASX:RMS) upgrades full year production guidance

22 Jun 2020 - Gold miner Ramelius Resources (ASX:RMS) has upgraded its full year production guidance to between 225,000 ounces and 230,000 ounces.

10AugAugust 10, 2020

Aurizon (ASX:AZJ) launches $300 million buyback as profit increases

10 Aug 2020 - Aurizon (ASX:AZJ) reports a 28% increase in net profit to $605 million as the rail freight operator launches a $300 million buyback.

15AprApril 15, 2020

USFDA grants fee waiver to Cyclopharm (ASX:CYC) for Technegas application

14 Apr 2020 - Cyclopharm (ASX:CYC) is pleased to announce that the United States Food and Drug Administration (USFDA) has granted the Company a full application fee waiver of USD $2.9 million related to its recently submitted New Drug Application (NDA) for Technegas.